{"id":"NCT00467259","sponsor":"Warner Chilcott","briefTitle":"Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women","officialTitle":"A Randomized, Double-Blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2007-04-30","resultsPosted":"2011-12-15","lastUpdate":"2011-12-15"},"enrollment":1271,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypoactive Sexual Desire Disorder"],"interventions":[{"type":"DRUG","name":"Testosterone Transdermal System","otherNames":[]},{"type":"DRUG","name":"Placebo patch","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Testosterone","type":"EXPERIMENTAL"}],"summary":"This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.","primaryOutcome":{"measure":"Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1","timeFrame":"52 weeks","effectByArm":[{"arm":"Placebo","deltaMin":0,"sd":null},{"arm":"Testosterone","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"1.0000"}]},"eligibility":{"minAge":"45 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":115,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":251},"commonTop":["Application Site Reaction","Weight Increased","Hirsutism","Upper Respiratory Tract Infection","Hypertension"]}}